These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 24618085)

  • 1. Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers.
    Wendt MK; Taylor MA; Schiemann BJ; Sossey-Alaoui K; Schiemann WP
    Breast Cancer Res; 2014 Mar; 16(2):R24. PubMed ID: 24618085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TGF-β stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer.
    Wendt MK; Schiemann BJ; Parvani JG; Lee YH; Kang Y; Schiemann WP
    Oncogene; 2013 Apr; 32(16):2005-15. PubMed ID: 22710711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug-resistant breast cancer.
    Abdullah A; Akhand SS; Paez JSP; Brown W; Pan L; Libring S; Badamy M; Dykuizen E; Solorio L; Andy Tao W; Wendt MK
    Oncogene; 2021 Jan; 40(2):322-333. PubMed ID: 33128042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer.
    Brown WS; Tan L; Smith A; Gray NS; Wendt MK
    Mol Cancer Ther; 2016 Sep; 15(9):2096-106. PubMed ID: 27371729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer.
    Wendt MK; Taylor MA; Schiemann BJ; Schiemann WP
    Mol Biol Cell; 2011 Jul; 22(14):2423-35. PubMed ID: 21613543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of NCAM/FGFR1 signaling suppresses EMT program in human proximal tubular epithelial cells.
    Životić M; Tampe B; Müller G; Müller C; Lipkovski A; Xu X; Nyamsuren G; Zeisberg M; Marković-Lipkovski J
    PLoS One; 2018; 13(11):e0206786. PubMed ID: 30383875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXC1 Regulates FGFR1 Isoform Switching to Promote Invasion Following TGFβ-Induced EMT.
    Hopkins A; Coatham ML; Berry FB
    Mol Cancer Res; 2017 Oct; 15(10):1341-1353. PubMed ID: 28684636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TGF-β1 promotes epithelial-to-mesenchymal transition and stemness of prostate cancer cells by inducing PCBP1 degradation and alternative splicing of CD44.
    Chen Q; Gu M; Cai ZK; Zhao H; Sun SC; Liu C; Zhan M; Chen YB; Wang Z
    Cell Mol Life Sci; 2021 Feb; 78(3):949-962. PubMed ID: 32440711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting.
    Cheng T; Roth B; Choi W; Black PC; Dinney C; McConkey DJ
    PLoS One; 2013; 8(2):e57284. PubMed ID: 23468956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression.
    Kim SH; Ryu H; Ock CY; Suh KJ; Lee JY; Kim JW; Lee JO; Kim JW; Kim YJ; Lee KW; Bang SM; Kim JH; Lee JS; Ahn JB; Kim KJ; Rha SY
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30326563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.
    Brown WS; Akhand SS; Wendt MK
    Oncotarget; 2016 Dec; 7(50):83424-83436. PubMed ID: 27825137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engagement of I-branching {beta}-1, 6-N-acetylglucosaminyltransferase 2 in breast cancer metastasis and TGF-{beta} signaling.
    Zhang H; Meng F; Wu S; Kreike B; Sethi S; Chen W; Miller FR; Wu G
    Cancer Res; 2011 Jul; 71(14):4846-56. PubMed ID: 21750175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The FGFR1 inhibitor PD173074 induces mesenchymal-epithelial transition through the transcription factor AP-1.
    Nguyen PT; Tsunematsu T; Yanagisawa S; Kudo Y; Miyauchi M; Kamata N; Takata T
    Br J Cancer; 2013 Oct; 109(8):2248-58. PubMed ID: 24045665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.
    Ji Q; Liu X; Han Z; Zhou L; Sui H; Yan L; Jiang H; Ren J; Cai J; Li Q
    BMC Cancer; 2015 Mar; 15():97. PubMed ID: 25884904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted inactivation of β1 integrin induces β3 integrin switching, which drives breast cancer metastasis by TGF-β.
    Parvani JG; Galliher-Beckley AJ; Schiemann BJ; Schiemann WP
    Mol Biol Cell; 2013 Nov; 24(21):3449-59. PubMed ID: 24006485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNFAIP3 is required for FGFR1 activation-promoted proliferation and tumorigenesis of premalignant DCIS.COM human mammary epithelial cells.
    Yang M; Yu X; Li X; Luo B; Yang W; Lin Y; Li D; Gan Z; Xu J; He T
    Breast Cancer Res; 2018 Aug; 20(1):97. PubMed ID: 30111373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to FGFR1-targeted therapy leads to autophagy via TAK1/AMPK activation in gastric cancer.
    Peng R; Chen Y; Wei L; Li G; Feng D; Liu S; Jiang R; Zheng S; Chen Y
    Gastric Cancer; 2020 Nov; 23(6):988-1002. PubMed ID: 32617693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway.
    Balanis N; Wendt MK; Schiemann BJ; Wang Z; Schiemann WP; Carlin CR
    J Biol Chem; 2013 Jun; 288(25):17954-67. PubMed ID: 23653350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.
    Quintanal-Villalonga Á; Ferrer I; Guruceaga E; Cirauqui C; Marrugal Á; Ojeda L; García S; Zugazagoitia J; Muñoz-Galván S; Lopez-Rios F; Montuenga L; Vicent S; Molina-Pinelo S; Carnero A; Paz-Ares L
    EBioMedicine; 2020 Mar; 53():102683. PubMed ID: 32114392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.